Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast can...
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms
About this item
Full title
Author / Creator
Sigurjonsdottir, Gudbjörg , De Marchi, Tommaso , Ehinger, Anna , Hartman, Johan , Bosch, Ana , Staaf, Johan , Killander, Fredrika , Niméus, Emma , Övriga starka forskningsmiljöer , LUCC: Lund University Cancer Centre , Department of Laboratory Medicine , Division of Translational Cancer Research , Biomarkers and epidemiology , Bröstcancer-genetik , Biomarkörer och Epi , Section I , Breast cancer treatment , Department of Clinical Sciences, Lund , Bröst/lungcancer , Lund University , Avdelningen för translationell cancerforskning , Institutionen för laboratoriemedicin , Sektion V , Profile areas and other strong research environments , Section V , Kirurgi, Lund , Breastcancer-genetics , Medicinsk onkologi , Breast/lungcancer , Faculty of Medicine , Medicinska fakulteten , Other Strong Research Environments , Molecular therapeutics in breast cancer , Molekylära behandlingsstrategier vid bröstcancer , Patologi, Lund , Forskningsgrupp Lungcancer , Breast cancer Proteogenomics , Institutionen för kliniska vetenskaper, Lund , Lunds universitet , Research Group Lung Cancer , Sektion I , Surgery (Lund) , Profilområden och andra starka forskningsmiljöer , Bröstcancer Proteogenomik , Medical oncology , Bröstcancerbehandling , Pathology, Lund , Breast/lung cancer and LUCC: Lunds universitets cancercentrum
Publisher
London: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Background Immunohistochemical (IHC) PD-L1 expression is commonly employed as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC). However, IHC evaluation methods are non-uniform and further studies are needed to optimize clinical utility. Methods We compared the concordance, prognostic value and gene expression b...
Alternative Titles
Full title
Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms
Authors, Artists and Contributors
Author / Creator
De Marchi, Tommaso
Ehinger, Anna
Hartman, Johan
Bosch, Ana
Staaf, Johan
Killander, Fredrika
Niméus, Emma
Övriga starka forskningsmiljöer
LUCC: Lund University Cancer Centre
Department of Laboratory Medicine
Division of Translational Cancer Research
Biomarkers and epidemiology
Bröstcancer-genetik
Biomarkörer och Epi
Section I
Breast cancer treatment
Department of Clinical Sciences, Lund
Bröst/lungcancer
Lund University
Avdelningen för translationell cancerforskning
Institutionen för laboratoriemedicin
Sektion V
Profile areas and other strong research environments
Section V
Kirurgi, Lund
Breastcancer-genetics
Medicinsk onkologi
Breast/lungcancer
Faculty of Medicine
Medicinska fakulteten
Other Strong Research Environments
Molecular therapeutics in breast cancer
Molekylära behandlingsstrategier vid bröstcancer
Patologi, Lund
Forskningsgrupp Lungcancer
Breast cancer Proteogenomics
Institutionen för kliniska vetenskaper, Lund
Lunds universitet
Research Group Lung Cancer
Sektion I
Surgery (Lund)
Profilområden och andra starka forskningsmiljöer
Bröstcancer Proteogenomik
Medical oncology
Bröstcancerbehandling
Pathology, Lund
Breast/lung cancer
LUCC: Lunds universitets cancercentrum
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a009212643f448b9bbced5c2d5101159
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a009212643f448b9bbced5c2d5101159
Other Identifiers
ISSN
1465-542X,1465-5411
E-ISSN
1465-542X
DOI
10.1186/s13058-023-01724-2
How to access this item
ERROR: Invalid URL specified.
